Key terms
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GNPX news
Mar 25
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 25
6:11am ET
Genprex initiated with a Buy at H.C. Wainwright
Mar 19
1:27pm ET
Genprex announces $6.5M registered direct offering priced at the market
Mar 19
8:56am ET
Genprex to sell 1.54M shares at $4.215 in registered direct offering priced ATM
Mar 19
8:39am ET
Genprex to sell 1.54M shares at $4.215 per share
Mar 12
9:02am ET
Genprex receives Notice of Patent Grant for Korean patent
Feb 07
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 07
8:19am ET
Genprex expands nonclinical programs to study TUSC2
Feb 06
4:23am ET
Genprex Launches Phase 2a Reqorsa Trial Expansion
Feb 05
7:36am ET
Genprex: First person dosed in Phase 2a expansion of Acclaim-1 trial
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
7:50pm ET
Genprex trading halted, news pending
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
8:43am ET
Genprex announces 1-for-40 reverse split
No recent news articles are available for GNPX
No recent press releases are available for GNPX
GNPX Financials
Key terms
Ad Feedback
GNPX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GNPX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range